Patient support group welcomes NICE decision to re-appraise Vidaza

London, 26 July 2010 – The MDS UK Patient Support Group has welcomed the decision announced today by the National Institute for Health and Clinical Excellence (NICE) that it will re-appraise the use of Vidaza (azacitidine)in patients with higher-risk myelodysplastic syndrome (MDS)- a group of debilitating bone marrow diseases.

Read full story

Cancer patient support groups to appeal negative NICE decision

The MDS UK Patient Support Group has announced that it has lodged an appeal against the negative recommendation issued earlier this month by the National Institute for Health and Clinical Excellence (NICE) for the use of Vidaza (azacitidine) in patients with higher-risk myelodysplastic syndrome (MDS).

Read full story

Macmillan Pre-election Campaign

The next Government has the power to invest in the future of cancer care. We need every parliamentary candidate to make a firm commitment to cancer support, and you can make this happen.

Read full story

Please Support Our NICE Campaign Appeal

On 4th March 2010, NICE published their final decision not to recommend the use of azacitidine (Vidaza) to treat patients with MDS in the NHS, despite its proven ability to extend patient survival and significantly improve quality of life…

Read full story
Free donations by shopping